Molina (MOH) Q3 2025 Earnings Call Transcript

Molina Healthcare cut 2025 adjusted EPS guidance to about $14 from $19, a $5 per share reduction, after Q3 adjusted EPS came in at $1.84 on elevated medical costs and a 92.6% consolidated MCR. Marketplace was the main drag, with Q3 MCR of 95.6% and full-year MCR guidance of 89.7%, while Medicaid and Medicare also saw higher utilization and rate pressure. The company raised full-year premium revenue guidance to $42.5 billion, resumed aggressive buybacks, and outlined a $46 billion 2026 revenue target, but near-term profitability remains under pressure.

Analysis

MOH’s reset is more than a one-quarter miss; it exposes a pricing lag in managed care that can persist into 2026 if state actuarial processes stay behind utilization. The key second-order effect is that the company is intentionally shrinking its least predictable book while leaning harder into Medicaid and duals, which should improve mix over time but also makes near-term earnings more sensitive to state rate timing and any further utilization surprise. That creates a classic “good long-term business, bad next two quarters” setup, especially because the market will likely focus on whether the 2026 earnings floor is truly stable or just the first step down in a still-moving trend line.

The most important hidden variable is not the headline MCR, but whether state rates catch up fast enough before the current cost inflection fully washes into new contracts. If rates rebase with a 6-12 month lag, MOH may see a mechanically better 2026 exit rate even if absolute medical cost levels remain elevated; if not, the company could be forced to choose between preserving margins and preserving membership, especially in Marketplace where competitive position is being intentionally sacrificed. The upside case is that management’s guidance math proves conservative and embedded earnings start to convert once implementation drag rolls off, but that is contingent on no re-acceleration in utilization in Q4/Q1.

For competitors, the pressure shifts onto smaller regional Medicaid plans and ACA carriers with weaker scale, because MOH is signaling it will selectively acquire revenue only at or near book and only where rate adequacy can be improved. That implies a likely wave of consolidation pressure in underfunded Medicaid markets, with hospitals and pharmacy utilization management likely to remain a source of friction. The market may be underestimating how quickly MOH can reprice away from bad exchange geographies; the bigger risk is that Medicaid and Medicare trend stay sticky, delaying the margin snapback longer than the company’s tone suggests.

Key Decisions for Investors

• Short MOH on any strength over the next 1-3 weeks; use a tactical trade with a stop above the post-earnings gap-fill level. Thesis: guidance cuts and exchange de-risking reduce the quality of 2026 earnings, while near-term optics remain tied to utilization rather than rate recovery.
• Pair trade: long CNC / short MOH for 3-6 months. If Medicaid rate adequacy improves broadly, higher-beta managed Medicaid peers with less ACA drag should outperform MOH’s more complicated mix.
• Buy MOH put spreads expiring after the Q4 print (3-5 month tenor). Risk/reward is attractive if the market starts pricing a lower 2026 baseline or questions whether Q4 EPS guidance is too optimistic.
• Watch ELV and UNH as read-through beneficiaries for Medicaid/duals scale; if MOH is forced into a prolonged de-risking cycle, larger diversified peers should capture share and pricing discipline.
• Avoid adding long exposure until state rate filings and first-quarter utilization data confirm that trend is flattening; the earliest credible reversal catalyst is 1H26 rate approvals, not the current quarter.